1 billion people are at risk of infection with leishmaniasis, a neglected disease strongly linked to poverty. There’s no single, simple cure: current treatments are complex and need to be adapted to the form of the disease and geographical region.
Fabiana Alves, Head of Visceral Leishmaniasis Clinical Programme, and Charles Mowbray, Discovery Director, explain why we are working towards new generation treatments for leishmaniasis.
More about visceral leishmaniasis
